AMEDISYS INC0000896262false00008962622024-07-242024-07-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 24, 2024
Commission File Number: 0-24260

image0.jpg
 
AMEDISYS, INC.
(Exact Name of Registrant as specified in its Charter) 
  
Delaware
11-3131700
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
3854 American Way, Suite A, Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662
(Registrant’s telephone number, including area code) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareAMEDThe NASDAQ Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
 




SECTION 2 — FINANCIAL INFORMATION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On July 24, 2024, Amedisys, Inc. ("we," "us," "our," or "the Company") issued a press release (the “Press Release”) announcing its financial results for the three and six-month periods ended June 30, 2024. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information presented in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered “filed” under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.
SECTION 7 – REGULATION FD
ITEM 7.01. REGULATION FD DISCLOSURE

Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

In addition, a copy of the Company's second quarter supplemental slides are attached to this report as Exhibit 99.2 and incorporated herein by reference.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.




SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS



Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
AMEDISYS, INC.
(Registrant)

By:    /s/ Scott G. Ginn
    Scott G. Ginn
    Chief Operating Officer, Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)

DATE: July 24, 2024



Exhibit 99.1
draftof8k050418image1.gif
            
AMEDISYS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

BATON ROUGE, Louisiana (July 24, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2024.
Three-Month Periods Ended June 30, 2024 and 2023

•Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.
•Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.
•Net income attributable to Amedisys, Inc. per diluted share of $0.98 compared to net loss attributable to Amedisys, Inc. per diluted share of $2.46 in 2023.

Adjusted Quarterly Results*

•Adjusted EBITDA of $73.2 million compared to $74.6 million in 2023.
•Adjusted net income attributable to Amedisys, Inc. of $43.5 million compared to $44.9 million in 2023.
•Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.32 compared to $1.37 in 2023.

Six-Month Periods Ended June 30, 2024 and 2023

•Net service revenue increased $53.2 million to $1,162.6 million compared to $1,109.4 million in 2023.
•Net income attributable to Amedisys, Inc. of $46.7 million, which is inclusive of merger-related expenses totaling $32.6 million ($31.3 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $55.0 million, which is inclusive of merger-related expenses totaling $126.2 million ($126.2 million, net of tax) in 2023.
•Net income attributable to Amedisys, Inc. per diluted share of $1.42 compared to net loss attributable to Amedisys, Inc. per diluted share of $1.69 in 2023.

Adjusted Year to Date Results*

•Adjusted EBITDA of $133.0 million compared to $132.5 million in 2023.
•Adjusted net income attributable to Amedisys, Inc. of $77.5 million compared to $77.6 million in 2023.
•Adjusted net income attributable to Amedisys, Inc. per diluted share of $2.35 compared to $2.38 in 2023.



* See pages 2 and 13 - 14 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.
The supplemental slides provided in connection with the second quarter 2024 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the second quarter results.
1

Non-GAAP Financial Measures
This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income (loss) attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net income attributable to Amedisys, Inc., defined as net income (loss) attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items; and (3) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share calculated in accordance with GAAP excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to, the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.
Additional Information
Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is in-patient hospital, palliative and skilled nursing facility ("SNF") care in their homes, home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease or hospice care at the end of life. More than 3,000 hospitals and 110,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 18,800 employees in 519 care centers within 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 469,000 patients every year. For more information about the Company, please visit: www.amedisys.com.
We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.
Forward-Looking Statements
When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the costs related to the proposed merger; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or
2

undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Contact:    Investor Contact:                Media Contact:            
Amedisys, Inc.                    Amedisys, Inc.
        Nick Muscato                    Kendra Kimmons
        Chief Strategy Officer             Vice President, Marketing & Communications
    (615) 928- 5452                    (225) 299-3720
        IR@amedisys.com             kendra.kimmons@amedisys.com
    

3

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)
 For the Three-Month 
Periods Ended June 30,		For the Six-Month
Periods Ended June 30,
 2024202320242023
Net service revenue$591,187 $552,968 $1,162,601 $1,109,357 
Operating expenses:
Cost of service, inclusive of depreciation326,933 297,455 648,470 612,465 
General and administrative expenses:
Salaries and benefits129,323 125,504 257,269 251,843 
Non-cash compensation7,828 9,083 15,261 12,356 
Merger-related expenses11,901 19,451 32,568 20,171 
Depreciation and amortization4,386 4,725 8,657 9,168 
Other58,602 58,955 116,543 123,180 
Total operating expenses538,973 515,173 1,078,768 1,029,183 
Operating income52,214 37,795 83,833 80,174 
Other income (expense):
Interest income1,617 742 3,344 1,148 
Interest expense(7,895)(7,502)(16,014)(15,019)
Equity in earnings from equity method investments1,515 7,991 2,425 8,114 
Merger termination fee— (106,000)— (106,000)
Miscellaneous, net1,779 4,743 2,869 4,061 
Total other expense, net(2,984)(100,026)(7,376)(107,696)
Income (loss) before income taxes49,230 (62,231)76,457 (27,522)
Income tax expense(16,657)(18,250)(29,290)(28,050)
Net income (loss)32,573 (80,481)47,167 (55,572)
Net (income) loss attributable to noncontrolling interests(272)206 (466)543 
Net income (loss) attributable to Amedisys, Inc.$32,301 $(80,275)$46,701 $(55,029)
Basic earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders$0.99 $(2.46)$1.43 $(1.69)
Weighted average shares outstanding32,706 32,579 32,688 32,568 
Diluted earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders$0.98 $(2.46)$1.42 $(1.69)
Weighted average shares outstanding33,047 32,579 32,992 32,568 

4

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)
June 30, 2024
(unaudited)		December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents$149,883 $126,450 
Restricted cash7,475 12,413 
Patient accounts receivable356,909 313,373 
Prepaid expenses15,510 14,639 
Other current assets26,125 30,060 
Total current assets555,902 496,935 
Property and equipment, net of accumulated depreciation of $98,850 and $92,42244,654 41,845 
Operating lease right of use assets84,692 88,939 
Goodwill1,244,679 1,244,679 
Intangible assets, net of accumulated amortization of $16,259 and $14,008100,832 102,675 
Other assets86,609 85,097 
Total assets$2,117,368 $2,060,170 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$26,626 $28,237 
Payroll and employee benefits136,118 136,835 
Accrued expenses147,038 140,049 
Termination fee paid by UnitedHealth Group106,000 106,000 
Current portion of long-term obligations37,747 36,314 
Current portion of operating lease liabilities26,447 26,286 
Total current liabilities479,976 473,721 
Long-term obligations, less current portion351,442 361,862 
Operating lease liabilities, less current portion59,007 62,751 
Deferred income tax liabilities47,212 40,635 
Other long-term obligations845 1,418 
Total liabilities938,482 940,387 
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding— — 
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,248,917 and 38,131,478 shares issued; 32,739,526 and 32,667,631 shares outstanding38 38 
Additional paid-in capital
803,361 787,177 
Treasury stock, at cost, 5,509,391 and 5,463,847 shares of common stock(472,821)(468,626)
Retained earnings794,626 747,925 
Total Amedisys, Inc. stockholders’ equity1,125,204 1,066,514 
Noncontrolling interests53,682 53,269 
Total equity1,178,886 1,119,783 
Total liabilities and equity$2,117,368 $2,060,170 


5

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING
(Amounts in thousands, except statistical information)
(Unaudited)
 For the Three-Month
Periods Ended June 30,		For the Six-Month
Periods Ended June 30,
 2024202320242023
Cash Flows from Operating Activities:
Net income (loss)$32,573 $(80,481)$47,167 $(55,572)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)6,358 6,199 12,496 11,893 
Non-cash compensation8,298 9,108 16,184 12,381 
Amortization and impairment of operating lease right of use assets8,534 8,349 17,100 16,971 
(Gain) loss on disposal of property and equipment(23)426 (19)356 
Loss on personal care divestiture— — — 2,186 
Merger termination fee— 106,000 — 106,000 
Deferred income taxes3,983 5,332 6,577 8,104 
Equity in earnings from equity method investments(1,515)(7,991)(2,425)(8,114)
Amortization of deferred debt issuance costs247 247 495 495 
Return on equity method investments548 966 718 2,753 
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable2,449 15,338 (44,357)7,862 
Other current assets4,823 5,817 3,127 1,689 
Operating lease right of use assets(1,027)(1,019)(2,069)(1,937)
Other assets215 355 370 244 
Accounts payable(10,345)(1,274)(1,693)(4,731)
Accrued expenses4,066 4,034 7,095 4,775 
Other long-term obligations18 (3,151)(573)(3,179)
Operating lease liabilities(6,897)(7,496)(14,429)(15,456)
Net cash provided by operating activities52,305 60,759 45,764 86,720 
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets— 6 21 25 
Proceeds from the sale of property and equipment— 100 — 100 
Purchases of property and equipment(1,385)(1,394)(4,055)(2,744)
Investments in technology assets(186)(6,457)(409)(6,667)
Investment in equity method investee— — (196)— 
Proceeds from personal care divestiture— — — 47,787 
Acquisitions of businesses, net of cash acquired— — — (350)
Net cash (used in) provided by investing activities(1,571)(7,745)(4,639)38,151 
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options— 75 — 75 
Proceeds from issuance of stock under employee stock purchase plan— 938 — 1,754 
Shares withheld to pay taxes on non-cash compensation(3,578)(2,180)(4,195)(3,488)
Noncontrolling interest contributions147 376 1,911 376 
Noncontrolling interest distributions(1,208)(427)(1,964)(712)
Purchase of noncontrolling interest— — — (800)
Proceeds from borrowings under revolving line of credit— 15,000 — 23,000 
Repayments of borrowings under revolving line of credit — (15,000)— (23,000)
Principal payments of long-term obligations(9,441)(5,680)(18,382)(60,993)
Payment of accrued contingent consideration— (4,055)— (4,055)
Net cash used in financing activities(14,080)(10,953)(22,630)(67,843)
Net increase in cash, cash equivalents and restricted cash36,654 42,061 18,495 57,028 
Cash, cash equivalents and restricted cash at beginning of period120,704 69,100 138,863 54,133 
Cash, cash equivalents and restricted cash at end of period$157,358 $111,161 $157,358 $111,161 
6

For the Three-Month 
Periods Ended June 30,		For the Six-Month 
Periods Ended June 30,
2024202320242023
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest$7,319 $6,377 $15,507 $13,031 
Cash paid for income taxes, net of refunds received$17,565 $15,468 $18,393 $15,820 
Cash paid for operating lease liabilities$7,924 $8,516 $16,498 $17,394 
Cash paid for finance lease liabilities$4,875 $2,864 $7,111 $5,321 
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities$3,774 $7,719 $10,947 $14,802 
Right of use assets obtained in exchange for finance lease liabilities$5,691 $7,154 $10,017 $27,944 
Reductions to right of use assets resulting from reductions to operating lease liabilities$— $14,994 $168 $15,135 
Reductions to right of use assets resulting from reductions to finance lease liabilities$623 $525 $1,119 $894 
Days revenue outstanding (1)52.1 43.4 52.1 43.4 

(1) Our calculation of days revenue outstanding at June 30, 2024 and 2023 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended June 30, 2024 and 2023, respectively.
7

AMEDISYS, INC. AND SUBSIDIARIES
SEGMENT INFORMATION
(Amounts in millions, except statistical information)
(Unaudited)
Segment Information - Home Health
 For the Three-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
Medicare$216.1 $219.8 
Non-Medicare161.3 130.0 
Net service revenue377.4 349.8 
Cost of service, inclusive of depreciation216.0 194.5 
Gross margin161.4 155.3 
General and administrative expenses92.4 90.2 
Depreciation and amortization1.9 1.2 
Operating income$67.1 $63.9 
Same Store Growth(1):
Medicare revenue(2 %)(1 %)
Non-Medicare revenue24 %10 %
Total admissions13 %4 %
Total volume(2)
9 %3 %
Key Statistical Data - Total(3):
Admissions110,188 97,453 
Recertifications46,170 45,808 
Total volume156,358 143,261 
Medicare completed episodes73,000 74,848 
Average Medicare revenue per completed episode(4)
$3,036 $3,005 
Medicare visits per completed episode(5)
12.2 12.5 
Visiting clinician cost per visit$106.00 $99.81 
Clinical manager cost per visit11.89 11.14 
Total cost per visit$117.89 $110.95 
Visits1,831,990 1,752,449 
8

 For the Six-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
Medicare$431.9 $435.2 
Non-Medicare309.5 257.9 
Net service revenue741.4 693.1 
Cost of service, inclusive of depreciation426.4 391.5 
Gross margin315.0 301.6 
General and administrative expenses183.4 179.3 
Depreciation and amortization3.7 2.3 
Operating income$127.9 $120.0 
Same Store Growth(1):
Medicare revenue(1 %)(4 %)
Non-Medicare revenue20 %11 %
Total admissions12 %6 %
Total volume(2)
8 %4 %
Key Statistical Data - Total(3):
Admissions222,403 199,416 
Recertifications90,131 89,133 
Total volume312,534 288,549 
Medicare completed episodes145,998 148,411 
Average Medicare revenue per completed episode(4)
$3,017 $2,990 
Medicare visits per completed episode(5)
12.0 12.4 
Visiting clinician cost per visit$105.68 $99.83 
Clinical manager cost per visit11.95 11.13 
Total cost per visit$117.63 $110.96 
Visits3,624,619 3,527,655 
(1)Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2)Total volume includes all admissions and recertifications.
(3)Total includes acquisitions, start-ups and denovos.
(4)Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.
(5)Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.


9

Segment Information - Hospice
 For the Three-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
Medicare$193.7 $188.2 
Non-Medicare10.3 11.0 
Net service revenue204.0 199.2 
Cost of service, inclusive of depreciation104.6 98.8 
Gross margin99.4 100.4 
General and administrative expenses48.7 47.9 
Depreciation and amortization0.8 0.7 
Operating income$49.9 $51.8 
Same Store Growth(1):
Medicare revenue3 %— %
Hospice admissions(2 %)(6 %)
Average daily census— %(2 %)
Key Statistical Data - Total(2):
Hospice admissions12,124 12,395 
Average daily census12,968 12,918 
Revenue per day, net$172.88 $169.47 
Cost of service per day$88.65 $84.03 
Average discharge length of stay90 90 
 For the Six-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
Medicare$383.7 $370.9 
Non-Medicare21.3 21.7 
Net service revenue405.0 392.6 
Cost of service, inclusive of depreciation209.9 200.2 
Gross margin195.1 192.4 
General and administrative expenses96.8 95.8 
Depreciation and amortization1.5 1.3 
Operating income$96.8 $95.3 
Same Store Growth(1):
Medicare revenue3 %— %
Hospice admissions(2 %)(6 %)
Average daily census— %(1 %)
Key Statistical Data - Total(2):
Hospice admissions24,781 25,393 
Average daily census12,867 12,825 
Revenue per day, net$172.96 $169.15 
Cost of service per day$89.63 $86.24 
Average discharge length of stay91 90 
(1)Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2)Total includes acquisitions and denovos.
10

Segment Information - Personal Care (1)

 For the Six-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
Medicare$— $— 
Non-Medicare— 15.0 
Net service revenue— 15.0 
Cost of service, inclusive of depreciation— 11.1 
Gross margin— 3.9 
General and administrative expenses— 2.3 
Depreciation and amortization— — 
Operating income$— $1.6 
Key Statistical Data - Total:
Billable hours— 440,464 
Clients served— 7,892 
Shifts— 191,379 
Revenue per hour$— $33.97 
Revenue per shift$— $78.19 
Hours per shift— 2.3
(1) We completed the sale of our personal care business on March 31, 2023.



Segment Information - High Acuity Care

 For the Three-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
Medicare$— $— 
Non-Medicare9.8 4.0 
Net service revenue9.8 4.0 
Cost of service, inclusive of depreciation6.4 4.2 
Gross margin3.4 (0.2)
General and administrative expenses5.4 5.3 
Depreciation and amortization0.8 0.8 
Operating loss$(2.8)$(6.3)
Key Statistical Data - Total:
Full risk admissions157 186 
Limited risk admissions675 348 
Total admissions832 534 
Total admissions growth56 %55 %
Full risk revenue per episode$10,124 $9,303 
Limited risk revenue per episode$6,816 $6,098 
Number of admitting joint ventures9 10 
11

 For the Six-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
Medicare$— $— 
Non-Medicare16.2 8.7 
Net service revenue16.2 8.7 
Cost of service, inclusive of depreciation12.2 9.7 
Gross margin4.0 (1.0)
General and administrative expenses11.3 9.7 
Depreciation and amortization1.7 1.6 
Operating loss$(9.0)$(12.3)
Key Statistical Data - Total:
Full risk admissions296 344 
Limited risk admissions1,297 807 
Total admissions1,593 1,151 
Total admissions growth38 %70 %
Full risk revenue per episode$10,100 $10,236 
Limited risk revenue per episode$6,799 $5,878 
Number of admitting joint venture markets9 10 




Segment Information - Corporate
 
 For the Three-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
General and administrative expenses$61.1 $69.6 
Depreciation and amortization0.9 2.0 
Total operating expenses$62.0 $71.6 
 For the Six-Month Periods
Ended June 30,
 20242023
Financial Information (in millions):
General and administrative expenses$130.1 $120.4 
Depreciation and amortization1.8 4.0 
Total operating expenses$131.9 $124.4 




12

AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
(Amounts in thousands)
(Unaudited)

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation:
For the Three-Month Periods
Ended June 30, 		For the Six-Month Periods
Ended June 30,
2024202320242023
Net income (loss) attributable to Amedisys, Inc.$32,301 $(80,275)$46,701 $(55,029)
Add:
        Income tax expense16,657 18,250 29,290 28,050 
        Interest expense, net6,278 6,760 12,670 13,871 
        Depreciation and amortization6,358 6,199 12,496 11,893 
        Certain items(1)
11,566 123,704 31,862 133,691 
Adjusted EBITDA(2)(5)
$73,160 $74,638 $133,019 $132,476 

Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:
For the Three-Month Periods
Ended June 30,		For the Six-Month Periods
Ended June 30,
2024202320242023
Net income (loss) attributable to Amedisys, Inc.$32,301 $(80,275)$46,701 $(55,029)
Add:
        Certain items(1)
11,240 125,153 30,788 132,642 
Adjusted net income attributable to Amedisys, Inc.(3)(5)
$43,541 $44,878 $77,489 $77,613 

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:
For the Three-Month Periods
Ended June 30,		For the Six-Month Periods
Ended June 30,
2024202320242023
Net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share$0.98 $(2.46)$1.42 $(1.69)
Add:
        Certain items(1)
0.34 3.83 0.93 4.06 
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(4)(5)
$1.32 $1.37 $2.35 $2.38 

13

(1)    The following details the certain items for the three and six-month periods ended June 30, 2024 and 2023:

Certain Items (in thousands):
For the Three-Month Periods
Ended June 30, 2024		For the Six-Month Periods
Ended June 30, 2024
(Income) Expense(Income) Expense
Certain Items Impacting General and Administrative Expenses:
Merger-related expenses$11,901 $32,568 
Certain Items Impacting Total Other Income (Expense):
Other (income) expense, net(335)(706)
Total$11,566 $31,862 
Net of tax$11,240 $30,788 
Diluted EPS$0.34 $0.93 
For the Three-Month Periods
Ended June 30, 2023		For the Six-Month Periods
Ended June 30, 2023
(Income) Expense(Income) Expense
Certain Items Impacting Cost of Service, Inclusive of Depreciation:
Clinical optimization and reorganization costs$— 114 
Certain Items Impacting General and Administrative Expenses:
Acquisition and integration costs1,101 2,768 
CEO transition3,435 4,185 
Merger-related expenses19,451 20,171 
Clinical optimization and reorganization costs567 3,737 
Personal care divestiture11 525 
Certain Items Impacting Total Other Income (Expense):
Other (income) expense, net (includes $106,000 merger termination fee)99,139 102,191 
Total$123,704 $133,691 
Net of tax$125,153 $132,642 
Diluted EPS$3.83 $4.06 


(2) Adjusted EBITDA is defined as net income (loss) attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
(3)    Adjusted net income attributable to Amedisys, Inc. is defined as net income (loss) attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(4)    Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income (loss) per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(5)    Adjusted EBITDA, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.
14
1 Amedisys Second Quarter 2024 Earnings Release Supplemental Slides July 24th, 2024 EXHIBIT 99.2

 
2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events. Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. www.amedisys.com NASDAQ: AMED We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business, clinical operations and control processes and SEC filings. FORWARD-LOOKING STATEMENTS EXHIBIT 99.2

 
3 OUR KEY AREAS OF FOCUS Strategic areas of focus and progress made during Q2’24 • Home Health: Total same store admissions +13% • Hospice: Total same store ADC +0.4% • High Acuity Care: Admissions +56% 1 Organic Growth • Quality: Amedisys Jul’24 STARS score of 4.32 • 92% of care centers at 4+ Stars based on Jul’24 final release • 40 Amedisys care centers rated at 5 Stars in the Jul’24 final release • Hospice quality – outperforming industry average in all hospice item set (HIS) categories 3 Clinical Initiatives • Focusing on optimizing RN / LPN & PT / PTA staffing ratios. • Current LPN Ratio: 47.9% (vs. 48.2% in 2Q’23) • Current PTA Ratio: 54.6% (vs. 54.2% in 2Q’23) 4 Capacity and Productivity • Pending merger with UnitedHealth Group Inc. 5 M&A 2 Recruiting / Retention • Targeting industry leading employee retention amongst all employee categories • Q2’24 Voluntary Turnover 19.2% 2024 Reimbursement • Final Hospice industry rule – Amedisys estimated impact +3.1% increase (effective 10/1/23) • Final Home Health industry rule – Amedisys estimated impact +0.8% increase (effective 1/1/24) 2025 Reimbursement • Proposed Hospice industry rule – industry estimated impact +2.6% increase (effective 10/1/24) • Proposed Home Health industry rule – industry estimated impact -1.7% decrease (effective 1/1/25) 6 Regulatory EXHIBIT 99.2

 
4 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 2Q 2024(1) EBITDA decreased $1 million over prior year on a $38 million increase in revenue. Excluding the impact of lower gains on the sale of fleet vehicles and a legal settlement, our EBITDA increased $3 million due to rate increases, home health volume growth, clinical optimization and reorganization initiatives and the recognition of savings generated on the first performance year of our risk-based palliative care contract. 1. The financial results for the three-month periods ended June 30, 2023 and June 30, 2024 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Same Store volume – Includes admissions and recertifications. 3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 4. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments. Growth Metrics: • Total Admissions: 832 (+56%) • Number of admitting JVs: 9 Other Statistics: • Patient Satisfaction: 86% High Acuity Care Adjusted Financial Results Same Store Volume (3): • Admissions: -2% • ADC: +0.4% Other Statistics: • Revenue per Day(5): $172.88 (+2.0%) • Cost per day: $88.14 (+5.3%) HospiceHome Health Same Store (2)(3) : • Total Admissions: +13% • Total Volume: +9% Other Statistics: • Revenue per Episode: $3,036 (+1.0%) • Visiting Clinician Cost per Visit: $105.25 (+6.1%) Amedisys Consolidated • Revenue: +7% • EBITDA: $73M • EBITDA Margin: 12.4% • EPS: $1.32 Amedisys Consolidated Amedisys Consolidated Balance Sheet & Cash Flow • Net debt: $241.3M • Net Leverage ratio: 1.0x • Revolver availability: $514.2M • CFFO: $52.3M • Free cash flow (4): $42.3M • DSO: 52.1 (vs. Q1’24 of 54.1 and up 8.7 days over prior year) $ in Millions, except EPS 2Q23 2Q24 Home Health 349.8$ 377.4$ Hospice 199.2 204.0 High Acuity Care 4.0 9.8 Total Revenue 553.0$ 591.2$ Gross Margin % 46.5% 45.0% Adjusted EBITDA 74.6$ 73.2$ 13.5% 12.4% Adjusted EPS 1.37$ 1.32$ Free cash flow (4) 54.1$ 42.3$ EXHIBIT 99.2

 
5 57.3% 12.9% 29.8% Home Health Revenue Medicare FFS Private Episodic Per Visit & Case Rate 63.8% 34.5% 1.7% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30-day period of care or 60-day episode of care, majority of which range from 90% - 100% of Medicare rates • Per Visit & Case Rate: Managed care, Medicaid and private payors who reimburse us per visit performed or per admission 95.0% 5.0% Hospice Revenue Medicare FFS Private Hospice Per Day Reimbursement: • Routine Care: Patient at home with symptoms controlled, ~97% of the Hospice care provided • Continuous Care: Patient at home with uncontrolled symptoms • Inpatient Care: Patient in facility with uncontrolled symptoms • Respite Care: Patient at facility with symptoms controlled • Home Health: 346 care centers; 34 states & D.C. • Hospice: 164 care centers; 31 states • High Acuity Care: 9 admitting joint ventures; 9 states; 34 referring hospitals • Total: 519 care centers/joint ventures; 37 states and D.C. OUR REVENUE SOURCES: 2Q’24 EXHIBIT 99.2

 
6 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – Q2 2024(1) • Medicare revenue per episode up 1.0% primarily due to the rate increase effective 1/1/2024. • Y/Y Total CPV up $6.79 (+6.2%) primarily due to raises, wage inflation, an increase in new hire pay and higher health insurance costs. • EBITDA margin decreased 40 basis points driven by a shift in our payor mix and higher labor costs. Home Health Highlights • Net revenue per day +2.0% primarily due to the +3.1% Hospice rate update effective 10/1/2023 partially offset by patient mix. • Cost per day up $4.47 (+5.3%) primarily due to raises, wage inflation, an increase in RN hires and higher health insurance costs partially offset by lower contractor utilization. • EBITDA margin down 140 basis points due to higher labor costs partially offset by the 2024 rate increase (effective 10/1/2023) and clinical optimization and reorganization initiatives. Hospice Highlights 1. The financial results for the three-month periods ended June 30, 2023 and June 30, 2024 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non- GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Pre-Corporate EBITDA does not include any corporate G&A expenses. 3. Same Store information represents the percent change in volume, admissions or ADC for the period as a percent of the volume, admissions or ADC of the prior period. 4. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. $ in Millions 2Q23 2Q24 Medicare 219.8$ 216.1$ Non-Medicare 130.0 161.3 Home Health Revenue $349.8 $377.4 Gross Margin % 44.7% 43.1% Pre-Corporate EBITDA (2) $66.7 $70.7 19.1% 18.7% Operating Statistics Same Store Growth(3 )(4 ) Total admissions 4% 13% Total volume 3% 9% Medicare revenue per episode $3,005 $3,036 Medicare recert rate 33.0% 31.8% Total cost per visit $110.35 $117.14 HOME HEALTH $ in Millions 2Q23 2Q24 Medicare 188.2$ 193.7$ Non-Medicare 11.0 10.3 Hospice Revenue $199.2 $204.0 Gross Margin % 50.6% 49.0% Pre-Corporate EBITDA (2) $53.5 $51.9 26.8% 25.4% Operating Statistics Admit growth - same store(3 )(4 ) -6% -2% ADC growth - same store(3 )(4 ) -2% 0.4% ADC 12,918 12,968 Avg. discharge length of stay 90 90 Revenue per day (net) $169.47 $172.88 Cost per day $83.67 $88.14 HOSPICE EXHIBIT 99.2

 
7 GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED (1,2) Notes: • Year over year total G&A as a percentage of revenue decreased 100 basis points • $7.3 million increase in total G&A is primarily due to planned wage increases, higher incentive compensation costs, an increase in our health insurance costs and higher legal and information technology fees partially offset by clinical optimization and reorganization initiatives • Total G&A increased ~$2 million sequentially primarily due to a seasonality driven increase in health insurance costs 1. The financial results for the three-month periods ended June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Adjusted G&A expenses do not include depreciation and amortization. Impacted by raises, incentive compensation costs and health insurance costs 34.1% 34.4% 34.5% 33.8% 33.1% 32.0% 34.0% 36.0% 2Q23 3Q23 4Q23 1Q24 2Q24 Total G&A as a Percent of Revenue G&A as a Percent of Revenue $ in Millions 2Q23 3Q23 4Q23 1Q24 2Q24 Home Health Segment - Total 90.1$ 91.3$ 92.7$ 91.0$ 92.4$ % of HH Revenue 25.8% 26.0% 25.8% 25.0% 24.5% Hospice Segment - Total 47.9 48.4 48.6 48.0 48.7 % of HSP Revenue 24.0% 24.2% 23.6% 23.9% 23.9% High Acuity Care Segment - Total 5.2 5.2 5.4 5.9 5.4 % of HAC Revenue 131.1% 119.2% 91.4% 92.5% 55.1% Total Corporate Expenses 45.2 46.2 50.3 48.4 49.2 % of Total Revenue 8.2% 8.3% 8.8% 8.5% 8.3% Total 188.4$ 191.1$ 197.0$ 193.3$ 195.7$ % of Total Revenue 34.1% 34.4% 34.5% 33.8% 33.1% 2Q23 3Q23 4Q23 1Q24 2Q24 Salary and Benefits 26.5 27.7 29.4 27.6 27.4 Other 15.1 14.9 16.9 16.6 17.4 Corp. G&A Subtotal 41.6 42.6 46.3 44.2 44.8 Non-cash comp 3.6 3.6 4.0 4.2 4.4 Adjusted Corporate G&A 45.2 46.2 50.3 48.4 49.2 EXHIBIT 99.2

 
8 $25.00 $50.00 $75.00 $100.00 $125.00 2Q23 1Q24 2Q24 Cost Per Visit (CPV) Salaries Contractors Benefits Transportation OPERATIONAL EXCELLENCE: HOME HEALTH COST PER VISIT (CPV)-ADJUSTED YOY Total CPV impacted by higher labor costs and health insurance costs. *Note: Direct comparison with industry competitors CPV calculation $99.21 $104.65 $105.25 Components 2Q’23 1Q’24 2Q’24 YoY Variance Detail Initiatives Salaries $73.35 $77.31 $76.99 $3.64 YoY increase due to planned wage increases, wage inflation, an increase in new hire pay and visit mix (discipline and visit type) Staffing mix optimization, productivity and scheduling improvement initiatives in place to help overcome salary increases Contractors $5.71 $6.38 $5.98 $0.27 YoY variance due to an increase in utilization Sequential variance due to lower rates partially offset by higher utilization Focused efforts on filling positions with full-time clinicians Benefits $13.10 $13.81 $15.00 $1.90 YoY variance due to higher payroll taxes on the salary increases described above and higher health insurance costs Sequential increase due to higher health insurance costs due to the seasonality of claims Focus on cost containment and spend optimization with specific focus on high-cost claims Transportation & Supplies $7.05 $7.15 $7.28 $0.23 YoY and sequential variances due to higher mileage costs *Visiting Clinician CPV $99.21 $104.65 $105.25 $6.04 Clinical Managers $11.14 $11.99 $11.89 $0.75 Fixed cost associated with non-visiting clinicians YoY variance due to planned wage increases and additional staff Unit cost reduced as volume increases Total CPV $110.35 $116.64 $117.14 $6.79 EXHIBIT 99.2

 
9 DRIVING TOP LINE GROWTH 3% 3% 5% 8% 9% 4% 4% 7% 10% 13% 0.0% 4.0% 8.0% 12.0% 16.0% 120,000 130,000 140,000 150,000 160,000 2Q23 3Q23 4Q23 1Q24 2Q24 Volume SS Volume Growth SS Admit Growth Home Health Growth Hospice Growth -2% -2% -0.2% 0.3% 0.4% -3.0% -2.0% -1.0% 0.0% 1.0% 12,600 12,700 12,800 12,900 13,000 2Q23 3Q23 4Q23 1Q24 2Q24 ADC SS ADC Growth EXHIBIT 99.2

 
10 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Jul 2024 HHC Final release with 93% of our providers (representing 92% of care centers) at 4+ Stars and 59% of our providers (representing 60% of care centers) at 4.5+ Stars. •21 Amedisys providers (representing 40 care centers) rated at 5 Stars. Notes: (1) Jul 2024 QPC Star Final performance period = Oct 2022 – Sep 2023 (ACH = CY 2022). (2) Jul 2024 PS Final performance period = Jan 2023 – Dec 2023. (3) QPC Star and PS Results for Amedisys Legacy providers only. (4) Only currently active care centers included in care center results. 3.00 3.50 4.00 4.50 Jan 2022 Apr 2022 Jul 2022 Oct 2022 Jan 2023 Apr 2023 Jul 2023 Oct 2023 Jan 2024 Apr 2024 Jul 2024 PS Industry Performance Amedisys PS Industry Avg PS Top Competitor 3.00 3.50 4.00 4.50 Jan 2022 Apr 2022 Jul 2022 Oct 2022 Jan 2023 Apr 2023 Jul 2023 Oct 2023 Jan 2024 Apr 2024 Jul 2024 QPC Industry Performance Amedisys QPC Industry Avg QPC Top Competitor Metric Oct 23 Release Jan 24 Release Apr 24 Final Jul 24 Final Quality of Patient Care 4.44 4.41 4.35 4.32 Entities at 4+ Stars 98% 96% 95% 93% Metric Oct 23 Release Jan 24 Release Apr 24 Final July 24 Final Patient Satisfaction Star 3.73 3.61 3.72 3.77 Performance Over Industry +2% +3% +2% +3% EXHIBIT 99.2

 
11 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. EXHIBIT 99.2

 
12 DEBT AND LIQUIDITY METRICS Net leverage ~1.0x 1. Net debt defined as total debt outstanding ($391.2M) less cash and cash equivalents ($149.9M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($247.6M). 3. Liquidity defined as the sum of cash balance and available revolving line of credit. Outstanding Term Loan 360.6$ Outstanding Revolver - Finance Leases 30.6 Total Debt Outstanding 391.2 Less: Deferred Debt Issuance Costs (2.1) Total Debt - Balance Sheet 389.1 Total Debt Outstanding 391.2 Less Cash & Cash Equivalents (Excludes Restricted Cash) (149.9) Net Debt (1) 241.3$ Leverage Ratio (net) (2) 1.0 Term Loan 450.0$ Revolver Size 550.0 Borrowing Capacity 1,000.0 Revolver Size 550.0 Outstanding Revolver - Letters of Credit (35.8) Available Revolver 514.2 Plus Cash & Cash Equivalents (Excludes Restricted Cash) 149.9 Total Liquidity (3) 664.1$ As of: 6/30/24 Credit Facility Outstanding Debt As of: 6/30/24 EXHIBIT 99.2

 
13 CASH FLOW STATEMENT HIGHLIGHTS (1) Total cash flow from operations for Q2-24 positively impacted by the collection of accounts receivable balances that were impacted by the Change Healthcare outage in Q1. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions 2Q23 3Q23 4Q23 1Q24 2Q24 GAAP net income (loss) (80.5)$ 25.6$ 1 9.0$ 1 4.6$ 32.6$ Changes in working capital 23.9 (56.4) 21 .4 (36.8) 1 .0 Depreciation and amortization 6.2 6.1 5.9 6.1 6.4 Non-cash compensation 9.1 7 .2 9.4 7 .9 8.3 Deferred income taxes 5.3 7 .3 5.2 2 .6 4.0 Merger termination fee 1 06.0 - - - - Other (9.3) 0.4 (0.6) (0.9) - Cash flow from operations 60.7 (9.8) 60.3 (6.5) 52.3 Capital expenditures - routine (0.9) (0.5) (0.9) (1 .2) (0.6) Required debt repay ments (5.7 ) (6.1 ) (8.9) (8.9) (9.4) Free cash flow 54.1$ (16.4)$ 50.5$ (16.6)$ 42.3$ EXHIBIT 99.2

 
14 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Other (income) expense, net includes the $106.0 million Option Care termination fee in 2Q23. Q2 adjustments primarily related to costs associated with pending merger. $000s Income Statement Line Item 2Q23 3Q23 4Q23 1Q24 2Q24 Cost of Service Clinical optimization and reorganization costs Cost of Serv ice, Inclusiv e of Depreciation -$ 282$ 1 99$ -$ -$ G&A Acquisition and integration costs General and Administrativ e Expenses 1 ,1 01 338 1 80 - - Clinical optimization and reorganization costs General and Administrativ e Expenses 567 466 1 ,81 9 - - Merger-related expenses General and Administrativ e Expenses 1 9,451 4,980 1 1 ,521 20,667 1 1 ,901 Personal Care div estiture General and Administrativ e Expenses 1 1 - - - - CEO transition General and Administrativ e Expenses 3,435 1 ,094 661 - - Other Items Other (income) expense, net (2) Total Other (Expense) Income, Net 99,1 39 (353) (534) (37 1 ) (335) Total 123,704$ 6,807$ 13,846$ 20,296$ 11,566$ EPS Impact 3.83$ 0.19$ 0.35$ 0.59$ 0.34$ EBITDA Impact 123,704$ 6,807$ 13,846$ 20,296$ 11,566$ EXHIBIT 99.2

 
15 Environmental, Social, Governance (E.S.G.) Considerations EXHIBIT 99.2

 
16 ENVIRONMENTAL, SOCIAL, GOVERNANCE (E.S.G.) CONSIDERATIONS Sustainable, high-quality, patient focused, home-based care model E n vi ro nmental, Social, Govern an ce Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental health has a strong correlation with physical health • A greener fleet – newer vehicles, in circulation for a shorter time, optimize fuel usage. Sophisticated scheduling practices reduce our clinicians’ driving time and fuel usage helping to minimize our carbon footprint • Virtual care centers, along with flexible working schedules and locations, have created fewer emissions Social • Amedisys strives to create an organizational culture and climate in which every individual is valued, all team members have a sense of belonging with one another and to the organization and feel empowered to do their best work • Provider of Home Health and Hospice services to frail, elderly patients in their most preferred care location – their homes • Highest quality Home Health company as measured by Quality of Patient Care Star scores (4.32 Stars) • The Amedisys Foundation was formed to provide support to our patients and employees. The Amedisys Foundation has two funds: the Patients’ Special Needs Fund and the Amedisys Employees 1st Fund. The Patients’ Special Needs Fund provides financial assistance to our home health, hospice and high acuity care patients during a difficult time Governance • Amedisys has a culture of compliance starting with oversight from the Board of Directors and cascading down to the care center level • Our Board of Directors operates several sub-committees including: • Quality of Care Committee • Compliance & Ethics Committee • Audit Committee • Compensation Committee • Nominating & Corporate Governance Committee • The Nominating and Corporate Governance Committee oversees our strategy on corporate social responsibility, including evaluating the impact of Company practices on communities and individuals, and develops and recommends to our Board of Directors for approval matters relating to the Company’s corporate social responsibility and ESG considerations EXHIBIT 99.2

 
v3.24.2
Cover Document
Jul. 24, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 24, 2024
Entity File Number 0-24260
Entity Registrant Name AMEDISYS INC
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 11-3131700
Entity Address, Street 3854 American Way
Entity Address, Suite Suite A
Entity Address, City Baton Rouge
Entity Address, State LA
Entity Address, Postal Zip Code 70816
City Area Code 225
Local Phone Number 292-2031
Title of each class Common Stock, par value $0.001 per share
Trading Symbol AMED
Name of each exchange on which registered NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000896262
Amendment Flag false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Amedisys (NASDAQ:AMED)
過去 株価チャート
から 6 2024 まで 7 2024 Amedisysのチャートをもっと見るにはこちらをクリック
Amedisys (NASDAQ:AMED)
過去 株価チャート
から 7 2023 まで 7 2024 Amedisysのチャートをもっと見るにはこちらをクリック